Patents by Inventor Paul Adam Schober

Paul Adam Schober has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained peptide-release formulation
    Patent number: 7309689
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: December 18, 2007
    Assignee: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Sustained peptide-release formulation
    Publication number: 20040180832
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Application
    Filed: March 25, 2004
    Publication date: September 16, 2004
    Applicant: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Sustained peptide-release formulation
    Patent number: 6777386
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: August 17, 2004
    Assignee: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Sustained peptide-release formulation
    Publication number: 20020052320
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15 % (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5 % (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Application
    Filed: November 26, 2001
    Publication date: May 2, 2002
    Applicant: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Sustained GnRH peptide-release formulation
    Patent number: 6337318
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Grant
    Filed: February 19, 1999
    Date of Patent: January 8, 2002
    Assignee: Peptech, Ltd.
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Synthetic polyunsaturated fatty acid analogues
    Patent number: 5998476
    Abstract: The invention provides polyunsaturated fatty acid compounds having antimalarial and/or neutrophil stimulatory activity, or anti-inflammatory activity. The polyunsaturated fatty acids contain a 16-26 carbon chain, 3-6 double bonds and are covalently coupled at the carboxylic acid group to an amino acid. It is preferred that the fatty acid contains 18-22 carbons and that the amino acid is glycine or aspartic acid. Preferred compounds are .gamma.-linolenic acid-glycine, .alpha.-linolenic acid-glycine, arachidonic acid-aspartic acid, eicosapentaenoic acid-aspartic acid and docosahexaenoic acid-aspartic acid.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: December 7, 1999
    Assignee: Peptide Technology Limited
    Inventors: Merilyn Joy Sleigh, Fred Widmer, Paul Adam Schober, Antonio Ferrante, Alfred Poulos, Deborah Ann Rathjen